|
Five recent papers using PODS® sustained growth factor delivery to reshape the future of regenerative medicine
|
|
1. Nerve Tissue Engineering (Materials Today Bio, 2025) NGF-β PODS® in aligned hydrogel scaffolds in guidance ducts achieving 0.8 mm/day neurite outgrowth - with superior cytoprotection and multipotency preservation compared to soluble NGF.
|
|
2. Retinal Ganglion Cell Transplantation (Translational Vision Science & Technology, 2025) BDNF and GDNF PODS® improved stem cell-derived retinal ganglion cell (RGC) transplantation outcomes for glaucoma treatment:
- 2.7-fold improvement in mouse RGC survival and 15-fold increase for human RGCs
- Enhanced neurite outgrowth (1053 μm vs 517 μm) and functional maturation in vitro
- Dual benefit: supported donor cell survival while providing neuroprotection to host RGCs, preserving retinal function in injury models
|
|
3. MSC Spheroids (Biomaterials Advances, 2025) NGF-β PODS® maintained MSC multipotency under oxidative stress while enhancing injury-responsive migration. PODS® treatment enabled significant improvements in MSC performance such as V-CAM expression (p<0.001) indicating appropriate injury response.
|
|
4. Vascular Grafts (Chemical Engineering Journal, 2024) First 3D bioprinted bilayer blood vessels using VEGF-165 and TGF-β1 PODS® achieved:
- 73.8% EC differentiation, 70.3% SMC differentiation
- Burst pressure increasing from 62→71 mmHg (day 0→14)
- Minimal platelet adhesion and ~1% hemolysis
- 7.32% vascular infiltration in vivo (p
|
|
5. Glaucoma Disease Modeling (Acta Biomaterialia, 2024) TGFβ-2 PODS® enabled controlled induction of pathological trabecular meshwork cell phenotypes, creating physiologically relevant in vitro disease models without requiring frequent cytokine supplementation.
|
|
|
|
Learn more about powerful technologies that are enabling research:
